This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Dermatologic Disorders  • Hypersensitivity  • Dermatologic Disorders, Other  • Drug Therapy  • Adverse Effects  • Allergy  • Alert me on articles by topic  Social Bookmarking   What's this?

Michael Paltiel, MD; Laura M. Gober, MD; April Deng, MD, PhD; Jamal Mikdashi, MD; Irena Alexeeva, MD; Sarbjit S. Saini, MD; Anthony A. Gaspari, MD

Arch Dermatol. 2008;144(9):1190-1194.

Background  Tumor necrosis factor (TNF) inhibitors such as adalimumab, etanercept, and infliximab play an increasingly important role in the management of a variety of chronic inflammatory disorders. With their increasing use, a wide spectrum of dermatological adverse effects, including injection site reactions and the development of dermatitis, have been recognized. Previous studies have implicated the role of the delayed-type hypersensitivity reaction in mediation of injection site reactions to etanercept. To our knowledge, there have been no published studies on immunologic mechanism of injection site reactions to adalimumab to date.

Observations  We describe 2 patients with a history of worsening injection site reactions to adalimumab. Findings from skin testing in both patients were suggestive of an immediate type I hypersensitivity reaction to adalimumab. A histamine release assay performed on peripheral blood leukocytes from both patients demonstrated significant histamine release on exposure to adalimumab. Furthermore, passive transfer of serum from one of the allergic patients to basophils from a nonatopic, healthy donor sensitized those cells to release significant amounts of histamine with exposure to adalimumab.

Conclusion  This study demonstrates that an IgE-mediated immediate type I hypersensitivity reaction plays a role in the mediation of worsening injection site reactions in some patients receiving adalimumab.

Author Affiliations: Departments of Dermatology (Drs Paltiel, Deng, and Gaspari), Rheumatology (Dr Mikdashi), and Neurology (Dr Alexeeva), University of Maryland, and Department of Allergy and Clinical Immunology, Johns Hopkins University (Drs Gober and Saini), Baltimore, Maryland.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

RELATED ARTICLE

This Month in Archives of Dermatology
Arch Dermatol. 2008;144(9):1100.
FULL TEXT